Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn's Disease Patients with Prescription Claims for Ustekinumab in the USA.
Journal
Drugs - real world outcomes
ISSN: 2199-1154
Titre abrégé: Drugs Real World Outcomes
Pays: Switzerland
ID NLM: 101658456
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
accepted:
18
05
2021
pubmed:
18
6
2021
medline:
18
6
2021
entrez:
17
6
2021
Statut:
ppublish
Résumé
Real-world evidence for how US Crohn's disease (CD) patients use ustekinumab is limited. The aim of this study was to describe the persistence, maintenance dosing, and pre-post corticosteroid and opioid use for CD patients in the USA treated with ustekinumab and those treated with adalimumab as a commonly used descriptive reference product. CD patients aged ≥ 18 years with ≥2 CD diagnoses between 1 October 2012 and 31 May 2018 and ≥ 1 new (i.e., no claim for at least 1 year) outpatient pharmacy claim for ustekinumab or adalimumab (first claim date = index date) on or after 26 September 2016 were selected from Symphony Health database. McNemar's tests were used to derive the p-values for pre-post changes in corticosteroid and opioid use within each treatment cohort. A total of 1073 ustekinumab and 2904 adalimumab patients met analysis criteria. Using a 90-day rule for discontinuation, persistence at 1 year post-index was 69.8% for ustekinumab and 65.1% for adalimumab. The majority received doses within ±30% of the approved labeling (ustekinumab 81.1%; adalimumab 78.8%). Doses higher than US package insert (PI) recommended maintenance dose were 7.0% for ustekinumab and 13.6% for adalimumab for 30% above PI, respectively; and 4.0% versus 9.4% for 50% above PI, respectively. Rates of pre-index biologic use suggest that patients treated with ustekinumab may have greater CD severity based on a greater percentage being biologic-experienced (ustekinumab 51.5% and adalimumab 8.4%). From pre- to post-index, the relative proportion of ustekinumab patients with ≥ 1 pharmacy claim for corticosteroids decreased by 25.5% (p < 0.0001) and opioids decreased by 8.4% (p = 0.0030). Results for adalimumab (a commonly used descriptive reference product in CD) showed generally similar trends. In this real-world study, persistence for ustekinumab remained high at 1 year. The majority of the patients in the ustekinumab cohort followed US PI recommended dosing. The percentage of patients with average dose above PI recommendations over 1 year were low for ustekinumab. Reductions in the proportion of patients with claims for corticosteroids or opioids were observed in patients using ustekinumab.
Sections du résumé
BACKGROUND
BACKGROUND
Real-world evidence for how US Crohn's disease (CD) patients use ustekinumab is limited.
OBJECTIVES
OBJECTIVE
The aim of this study was to describe the persistence, maintenance dosing, and pre-post corticosteroid and opioid use for CD patients in the USA treated with ustekinumab and those treated with adalimumab as a commonly used descriptive reference product.
METHODS
METHODS
CD patients aged ≥ 18 years with ≥2 CD diagnoses between 1 October 2012 and 31 May 2018 and ≥ 1 new (i.e., no claim for at least 1 year) outpatient pharmacy claim for ustekinumab or adalimumab (first claim date = index date) on or after 26 September 2016 were selected from Symphony Health database. McNemar's tests were used to derive the p-values for pre-post changes in corticosteroid and opioid use within each treatment cohort.
RESULTS
RESULTS
A total of 1073 ustekinumab and 2904 adalimumab patients met analysis criteria. Using a 90-day rule for discontinuation, persistence at 1 year post-index was 69.8% for ustekinumab and 65.1% for adalimumab. The majority received doses within ±30% of the approved labeling (ustekinumab 81.1%; adalimumab 78.8%). Doses higher than US package insert (PI) recommended maintenance dose were 7.0% for ustekinumab and 13.6% for adalimumab for 30% above PI, respectively; and 4.0% versus 9.4% for 50% above PI, respectively. Rates of pre-index biologic use suggest that patients treated with ustekinumab may have greater CD severity based on a greater percentage being biologic-experienced (ustekinumab 51.5% and adalimumab 8.4%). From pre- to post-index, the relative proportion of ustekinumab patients with ≥ 1 pharmacy claim for corticosteroids decreased by 25.5% (p < 0.0001) and opioids decreased by 8.4% (p = 0.0030). Results for adalimumab (a commonly used descriptive reference product in CD) showed generally similar trends.
CONCLUSIONS
CONCLUSIONS
In this real-world study, persistence for ustekinumab remained high at 1 year. The majority of the patients in the ustekinumab cohort followed US PI recommended dosing. The percentage of patients with average dose above PI recommendations over 1 year were low for ustekinumab. Reductions in the proportion of patients with claims for corticosteroids or opioids were observed in patients using ustekinumab.
Identifiants
pubmed: 34136998
doi: 10.1007/s40801-021-00264-5
pii: 10.1007/s40801-021-00264-5
pmc: PMC8605940
doi:
Types de publication
Journal Article
Langues
eng
Pagination
565-575Informations de copyright
© 2021. The Author(s).
Références
Crohn's & Colitis Foundation of America. The Facts about Inflammatory Bowel Diseases. 2019. Available from: https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf . Accessed 27 Apr 2020.
Rao BB, Click BH, Koutroubakis IE, et al. The cost of Crohn’s disease: varied health care expenditure patterns across distinct disease trajectories. Inflamm Bowel Dis. 2017;23(1):107–15.
doi: 10.1097/MIB.0000000000000977
van der Have M, van der Aalst KS, Kaptein AA, et al. Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8(2):93–106.
doi: 10.1016/j.crohns.2013.04.007
Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58(2):519–25.
doi: 10.1007/s10620-012-2371-5
Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517.
doi: 10.1038/ajg.2018.27
STELARA (ustekinumab) [package insert]. Titusville, NJ: Janssen Biotech, Inc; 2016.
Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–27.
doi: 10.1093/ibd/izz001
Obando C, Ding Z, Muser E, et al. Persistence, dose titration, and health care resource utilization among Crohn’s disease patients treated with ustekinumab: a real-world analysis in the United States. Adv Ther. 2020;37(5):2127–43.
doi: 10.1007/s12325-020-01276-3
Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507.
pubmed: 30873648
Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States. PLoS ONE. 2017;12(4):e0175099.
doi: 10.1371/journal.pone.0175099
Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.
doi: 10.1111/j.1524-4733.2007.00213.x
Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
doi: 10.1038/ctg.2015.63
Symphony Health. Symphony Health Fact Sheet. 2020. https://s3.us-east-1.amazonaws.com/prahs-symphony-health/resources/Symphony_IDV-Sheet_FINAL_JULY.pdf?mtime=20200702132440&focal=none . Accessed 30 Apr 2021.
Null K, Kumar V, Lissoos T, Luo M. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease. J Med Econ. 2018;21(11):1102–9.
doi: 10.1080/13696998.2018.1511568
Obando C, Woodruff K, Muser E, et al. P313 Steroid and opioid use among Crohn’s patients before and after initiation of ustekinumab. J Crohns Colitis. 2018;12(supplement_1):S259-s.
doi: 10.1093/ecco-jcc/jjx180.440
Ding B, Kallenbach L, Slipski L, Wilk A, O’Brien D, Guranlioglu D. Patient characteristics and healthcare resource utilization among patients with COPD new to LAMA/LABA fixed-dose combination treatment in US-based real-world practice. Int J Chron Obstruct Pulmon Dis. 2020;15:775–86.
doi: 10.2147/COPD.S238408
Govani SM, Lipson R, Noureldin M, et al. Adalimumab persistence for inflammatory bowel disease in veteran and insured cohorts. Am J Manag Care. 2018;24(12):e374–9.
pubmed: 30586485
pmcid: 6907164
Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease. Aliment Pharmacol Ther. 2014;39(10):1143–55.
doi: 10.1111/apt.12727
Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohns Colitis. 2013;7(2):154–60.
doi: 10.1016/j.crohns.2012.03.018
Manceur AM, Ding Z, Muser E, et al. Burden of Crohn’s disease in the United States: long-term healthcare and work-loss related costs. J Med Econ. 2020;23(10):1092–101.
doi: 10.1080/13696998.2020.1789649